Ask AI
ProCE Banner Activity

Implementing TROP-2–Directed ADC Therapy in EGFR-Mutated NSCLC: From Clinical Trial Evidence to Clinical Decision-making

Clinical Thought

The rapidly evolving evidence for TROP2-targeted ADCs is reshaping treatment options in advanced NSCLC, particularly in EGFR-mutated disease. Read our thoughts on how to interpret the latest data, sequence these agents in practice, and manage key toxicities as TROP2 ADC use expands.

Released: March 11, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner
ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the management of patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the significance of TROP2 expression in NSCLC and the therapeutic rationale for targeting TROP2 with antibody–drug conjugates

  • Compare and contrast potential indications, efficacy, and toxicity profiles among available and investigational agents targeting TROP2 in NSCLC

  • Analyze and integrate TROP2 ADCs for patients with NSCLC based on a comprehensive understanding of available clinical data and expert recommendations

  • Design a tailored supportive care plan to manage treatment-related adverse events in patients receiving HER2- or TROP2–targeted therapy, emphasizing quality of life and patient comfort

Disclosure

Primary Author

Matthew Gubens, MD, MS, FASCO: consultant/advisor/speaker: AstraZeneca, Bicycle, Bristol Myers Squibb, Cardinal Health, Catalyst, Foresight, Genentech, Johnson & Johnson, Natera, Nuvalent, OncoHost, Regeneron; researcher (paid to institution): Amgen, Johnson & Johnson, Merck, Trizell; data and safety monitoring committee: Samsung Bioepis.

Helena Yu, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Taiho, Takeda; researcher (paid to institution): AstraZeneca, Cullinan, Daiichi Sankyo, Janssen, SystImmune.